Sarepta Therapeutics slides on dystrophin/ clinical benefit questions

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Shares of Sarepta Therapeutics (SRPT -6.3%) are notably lower on the session.

The stock traded up on Friday as the market took a decidedly negative stance on data from a trial of Prosensa (RNA -1%) and GlaxoSmithKline's (GSK -0.2%) drisapersen (an eteplirsen competitor).

Today's weakness in SRPT shares may be attributable to a note from Cowen which suggests the drisapersen data highlights the debate regarding dystrophin as a surrogate endpoint.

The drisapersen data "underscores [the] point that no correlation can be drawn currently between dystrophin and clinical benefit," Cowen says.

Adam Feuerstein's take: "SRPT bears sticking to script. We knew they'd link poor drisapersen dystrophin data to eteplirsen."

Note: Cowen is still "bullish on SRPT shares."